In an interview with the Lymphoma Research Foundation (LRF), Dr. Peter Martin discusses mantle cell lymphoma (MCL), treatment options including transplantation, and what advice he would give to people who are newly diagnosed with MCL.
Debate exists among researchers on whether or when stem cell transplantation should be used in the treatment of MCL. Why do you think this is so?
“Some people feel that stem cell transplantation is likely to make a patient live longer and others feel that a long remission duration following a stem cell transplant means there are fewer lymphoma-related side effects, and everybody likes that idea.
On the other hand, autologous stem cell transplantation doesn’t cure MCL. There are limited data that suggest that it may allow people to live longer, and many patients may experience significant side effects but not have a very durable remission and a longer life. So that’s a very subjective sort of decision based on less than perfect evidence.
It’s our job as lymphoma doctors to help patients understand the potential benefits and the potential negative side effects to all treatment options so they can select a treatment that is best for them. There’s no right or wrong treatment option in many cases and it’s a matter of choosing the option that makes the most sense for that person at that point in time.”
The full interview can be read on the LRF’s website.